BridgeBio Pharma (BBIO) Hisse Özeti
Bir biyofarmasötik şirketi olan BridgeBio Pharma, Inc. genetik hastalıkları olan hastalar için ilaçlar keşfeder, geliştirir ve sunar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 1/6 |
| Temettüler | 0/6 |
BBIO Community Fair Values
Create NarrativeSee what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$25
FV
237.9% aşırı değerlenmiş içsel indirim95
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
BridgeBio Pharma, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$84.48 |
| 52 Haftanın En Yüksek Seviyesi | US$93.42 |
| 52 Haftanın En Düşük Seviyesi | US$46.29 |
| Beta | 0.98 |
| 1 Aylık Değişim | -1.64% |
| 3 Aylık Değişim | 30.61% |
| 1 Yıllık Değişim | 81.37% |
| 3 Yıllık Değişim | 171.90% |
| 5 Yıllık Değişim | 68.56% |
| Halka arzdan bu yana değişim | 206.64% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 25
BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside
BridgeBio Pharma's fair value estimate has been revised slightly higher to $105.26 per share from $102.71, as analysts refresh models around updated price targets and pipeline expectations, particularly for Attruby, acoramidis and BBP-418. Analyst Commentary Recent research updates on BridgeBio Pharma reflect a mix of optimism and caution, with analysts recalibrating price targets as Attruby, acoramidis, BBP-418 and infigratinib progress through launch and regulatory milestones.
Yeni Anlatı • Jul 19
Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.Seeking Alpha • Jul 12
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
Summary BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market. Recent $1B preferred equity raise secures BBIO's cash runway for at least 12 months, supporting ongoing NDA submissions and commercialization efforts. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • Jul 25
BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside
BridgeBio Pharma's fair value estimate has been revised slightly higher to $105.26 per share from $102.71, as analysts refresh models around updated price targets and pipeline expectations, particularly for Attruby, acoramidis and BBP-418. Analyst Commentary Recent research updates on BridgeBio Pharma reflect a mix of optimism and caution, with analysts recalibrating price targets as Attruby, acoramidis, BBP-418 and infigratinib progress through launch and regulatory milestones.Yeni Anlatı • Jul 19
Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins
The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.Seeking Alpha • Jul 12
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
Summary BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026 U.S. net product revenue reaching $180.6 million, and is pursuing further pipeline expansion. Positive phase 3 PROPEL 3 data for oral infigratinib in achondroplasia supports an NDA submission in Q3 2026, targeting a $2.9B global market. Recent $1B preferred equity raise secures BBIO's cash runway for at least 12 months, supporting ongoing NDA submissions and commercialization efforts. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 11
BBIO: Cardiomyopathy Launch And Rare Disease Filings Will Shape Next Phase
The analyst fair value estimate for BridgeBio Pharma has been raised from $76.00 to $80.00, reflecting updated Street price targets around $96 to $104 and analyst views that recent regulatory progress and ongoing launch execution support slightly higher projected growth, margins, and future P/E. Analyst Commentary Recent research on BridgeBio Pharma shows a mix of optimism around its rare disease portfolio and a more cautious stance from some bearish analysts who are focused on execution and valuation risks.
Anlatı Güncellemesi • Jun 22
BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares
BridgeBio Pharma's updated analyst price target framework reflects a modestly higher fair value estimate of about $136, as analysts factor in mixed Street revisions that incorporate recent Q1 model updates, new coverage tied to Attruby and the rare disease pipeline, and differing views on payer risks and the recent regulatory milestones. Analyst Commentary Street commentary on BridgeBio Pharma currently reflects a mix of enthusiasm around Attruby, the rare disease portfolio, and key regulatory updates, offset by caution around payer dynamics and how these factors could influence valuation over time.Anlatı Güncellemesi • Jun 05
BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside
Analysts raised their blended fair value estimate for BridgeBio Pharma by about $1.82 to roughly $102.71, citing fresh price targets around $98 to $104, growing confidence in the Attruby launch, the broader rare disease pipeline, and added visibility from BBP-418's FDA Priority Review. Analyst Commentary Street research on BridgeBio Pharma is mixed, with several firms adjusting price targets and ratings around the Attruby launch, pipeline milestones, and regulatory updates such as the Priority Review for BBP-418.Anlatı Güncellemesi • May 20
BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase
BridgeBio Pharma's fair value estimate has been trimmed by $4 to $76 as analysts balance a higher discount rate and more measured revenue growth against ongoing support for Attruby and the broader pipeline, as reflected in recent price target updates across the Street. Analyst Commentary Street research on BridgeBio continues to cluster around Attruby execution, valuation upside tied to pipeline milestones, and the impact of tafamidis settlement dynamics.Anlatı Güncellemesi • May 01
BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside
Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.Anlatı Güncellemesi • Apr 17
BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence
Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.Anlatı Güncellemesi • Apr 03
BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares
Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.Anlatı Güncellemesi • Mar 20
BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares
The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.Anlatı Güncellemesi • Mar 05
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026
The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.Anlatı Güncellemesi • Feb 19
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.Anlatı Güncellemesi • Feb 05
BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing
Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.Anlatı Güncellemesi • Jan 22
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026
Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.Anlatı Güncellemesi • Jan 07
BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing
Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.Anlatı Güncellemesi • Dec 24
BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead
BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.Anlatı Güncellemesi • Dec 10
BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond
Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.Anlatı Güncellemesi • Nov 26
BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals
BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.Anlatı Güncellemesi • Nov 10
BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions
BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.Anlatı Güncellemesi • Oct 27
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.Anlatı Güncellemesi • Oct 13
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.Anlatı Güncellemesi • Sep 29
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.Anlatı Güncellemesi • Sep 14
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.Anlatı Güncellemesi • Aug 30
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.Yeni Anlatı • Aug 10
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.Hissedar Getirileri
| BBIO | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 5.5% | 6.3% | 4.2% |
| 1Y | 81.4% | 40.9% | 20.6% |
Getiri vs. Endüstri: BBIO geçen yıl % 40.9 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: BBIO geçen yıl % 20.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: BBIO son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BBIO 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2015 | 837 | Neil Kumar | bridgebio.com |
Bir biyofarmasötik şirketi olan BridgeBio Pharma, Inc. genetik hastalıkları olan hastalar için ilaçlar keşfeder, geliştirir ve sunar. Şirket, vahşi tip veya transtiretin aracılı amiloidoz (ATTR-CM) kardiyomiyopatisinin tedavisi için yeni nesil oral küçük moleküllü, tama yakın bir TTR stabilizatörü olan Attruby'yi sunmaktadır; NULIBRY markası altında molibden kofaktör eksikliğinin tedavisi için sentetik siklik piranopterin monofosfatın intravenöz formülasyonu olan Fosdenopterin; ve Faz 3 klinik aşamasında olan veya akondroplazi ve hipokondroplazili çocukların tedavisi için oral bir FGFR1-3 seçici tirozin kinaz inhibitörü olan düşük doz infigratinib. Ayrıca, Otozomal Dominant Hipokalsemi Tip 1 (ADH1) ve Kronik Hipoparatiroidizm (CHP) tedavisi için faz 3 klinik çalışmada olan oral küçük moleküllü, kalsiyum algılama reseptörünün negatif allosterik modülatörü olan Encaleret'i geliştirmektedir; BBP-418, LGMD2I tedavisi için faz 3 klinik çalışmada olan araştırma amaçlı, oral yoldan uygulanan ve küçük moleküllü bir terapi; ve BBP-812, Canavan hastalığı için araştırma amaçlı bir adeno-ilişkili virüs (AAV) gen terapisi.
BridgeBio Pharma, Inc. Temel Bilgiler Özeti
| BBIO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$16.51b |
| Kazançlar(TTM) | -US$721.55m |
| Gelir(TTM) | US$579.96m |
28.5x
P/S Oranı-22.9x
F/K OranıBBIO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BBIO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$579.96m |
| Gelir Maliyeti | US$28.26m |
| Brüt Kâr | US$551.70m |
| Diğer Giderler | US$1.27b |
| Kazançlar | -US$721.55m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 10, 2026
| Hisse başına kazanç (EPS) | -3.69 |
| Brüt Marj | 95.13% |
| Net Kâr Marjı | -124.41% |
| Borç/Özkaynak Oranı | -109.0% |
BBIO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/09 14:28 |
| Gün Sonu Hisse Fiyatı | 2026/08/07 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
BridgeBio Pharma, Inc. 37 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Eliana Merle | Barclays |
| William Pickering | Bernstein |
| Jason Zemansky | BofA Global Research |